ACADIA Pharmaceuticals Inc. (ACAD) SEC Filings & Earnings Calls

R&D leadership transition risk; potential disruption to pipeline programs and strategic direction.

“Departure of EVP Head of R&D; replacement search ongoing; consulting arrangement only through year-end.”

Primary endpoint narrowly missed statistical significance; Phase 3 still ongoing with risk of failure.

“narrowly missed primary endpoint of SAPS H+D (p=0.0603)” · word for word

Derivative lawsuit settlement; potential governance distraction but no material financial liability disclosed.

“Stockholder derivative action settled; court preliminarily approved.”

Litigation and legal costs

“The Company is involved in securities class action, opt-out litigation, and derivative suits; a settlement of $1.5 million in attorneys' fees has been proposed but is subject to court approval.”

Generic competition for NUPLAZID

“Settlement agreements allow generic launches as early as 2036/2038, with potential earlier triggers; ongoing litigation with Zydus.”

Dependence on DAYBUE and NUPLAZID

“All revenue comes from two products; DAYBUE is still relatively new and subject to adoption and reimbursement risks.”

Milestone payment obligations

“Potential milestone payments up to $3.6 billion in aggregate for pipeline candidates, which could pressure cash flow if achieved.”

SG&A expense growth (19% YoY) outpacing revenue growth (16% YoY), indicating potential operating leverage pressure.

“SG&A expenses $160M vs $134M YoY, up 19.4%; revenue up 16%.”

Phase 2 remlifanserin readout in Alzheimer's disease psychosis (Sep-Oct 2026) is a binary catalyst with high uncertainty.

“Topline results from the Phase 2 remlifanserin study in Alzheimer's disease psychosis anticipated September to October 2026.” · word for word

Potential dilution from increased share authorization under equity plan.

“Increase of 5,209,670 shares authorized for issuance under the 2024 Equity Incentive Plan.”

Patent litigation risk

“The Company is engaged in patent infringement litigation regarding NUPLAZID with multiple generic manufacturers.”

Securities class action risk

“A putative securities class action complaint has been filed against the Company and certain executive officers.”

IRA impact on NUPLAZID

“The Company did not achieve its 2025 NUPLAZID net product sales target, despite strong operational performance, due to the one-year impact of the Inflation Reduction Act (IRA) adjustment.”

SG&A expense increase of 36% YoY may pressure margins if revenue growth slows.

“SG&A expenses $171M vs $126M prior year”

Dependence on DAYBUE and NUPLAZID for revenue; pipeline risk.

“Phase 2 remlifanserin study in Alzheimer's disease psychosis expected between August and October 2026” · word for word

Loss of key R&D leadership could impact pipeline execution; transition risk.

“Departure of Head of R&D; search for replacement initiated.”

IRA impact on NUPLAZID

“The Company did not achieve its 2025 NUPLAZID net product sales target, despite strong operational performance, due to the one-year impact of the Inflation Reduction Act (IRA) adjustment.” · word for word

Patent litigation risk

“The Company is engaged in patent infringement litigation regarding NUPLAZID with multiple generic manufacturers.”

Securities class action risk

“A putative securities class action complaint has been filed against the Company and certain executive officers.”

IRA Drug Pricing Pressure

“This unfavorable change of approximately $20.1 million related to the sales from October 1, 2022 to December 31, 2025, which increased our gross-to-net adjustments and reduced our net product sales of NUPLAZID.” · word for word

Pipeline Failure

“ACP-101 did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint... As a result, we do not intend to investigate ACP-101 any further.” · word for word

Cybersecurity Incident

“we were made aware of a cyberattack against one of the largest prescription processors in the country in February 2024 that impacted the ability for our specialty pharmacy partners to have payors provide authorizations for patient refills and new patient starts for certain of our products.” · word for word

Concentrated Ownership / Share Overhang

“On May 23, 2025, the SEC declared effective a registration statement that we filed on May 9, 2025 covering the sale of up to 43,576,075 shares of our common stock, which includes 492,407 shares of our common stock issuable upon the exercise of warrants that were owned by the Baker Entities as of April 30, 2025, and which represented approximately 26 percent ” · word for word

IRA rebate adjustment created non-recurring GAAP headwind; future IRA impact uncertain.

“received its first invoices under the IRA, which were higher than expected” · word for word

Dependence on NUPLAZID and DAYBUE for revenue; pipeline risk.

“revenue concentrated in two products”

Patent Litigation Risk

“The Company is involved in patent infringement lawsuits regarding NUPLAZID. A bench trial was conducted from December 3, 2024 to December 6, 2024... On June 9, 2025, the Federal Circuit issued a decision affirming the final judgement of the District Court in the Company's favor.”

Securities Class Action

“On April 19, 2021, a purported stockholder of the Company filed a putative securities class action complaint... The amended complaint seeks unspecified monetary damages and other relief.” · word for word

Dependence on two key products for revenue; pipeline still early-stage.

“Revenue entirely from NUPLAZID and DAYBUE; pipeline programs in Phase 2/3.”

Tax benefit from R&D expensing is one-time; net income may normalize.

“Tax benefit primarily resulted from a one-time impact from the One Big Beautiful Bill Act.” · word for word

Loss of board member and committee chair, though no disagreement noted.

“Resignation effective October 30, 2025.”